Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral

Clinical Therapeutics

Volumn 21, Issue 1, 1999, Pages 160-171

  Mendez, Robert ^a   Abboud, Hanna ^b   Burdick, James ^c   Copley, Brian ^d   Freeman, Richard ^e   Batiuk, Thomas D ^f   Cooney, Gerard F ^g   Barbeito, Ralph ^h  

^a National Institute of Transplantation Los Angeles   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d Tulane Multi Organ Transplant Center   (United States)

^e TUFTS MEDICAL CENTER   (United States)

^f INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^g TEMPLE UNIVERSITY HOSPITAL   (United States)

^h NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bioavailability; Cyclosporine; Pharmacokinetics; Transplant

Indexed keywords

CYCLOSPORIN A;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM ALLOWABLE CONCENTRATION; ORAL DRUG ADMINISTRATION;

EID: 0033048295     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)88276-4     Document Type: Article

References (22)

1. 1. Kasiske BL, Heim-Duthoy K, Rao KV, et al. The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients. Transplantation. 1988;46:716-722.
2. 2. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther. 1993;54:205-218.
3. 3. Ohlman S, Lindholm A, Hägglund H, et al. On the intraindividual variability and chronobiology of cyclosporine pharmacokinetics in renal transplantation. Eur J Clin Pharmacol. 1993;44:265-269.
4. 4. Kahan BD, Welsh M, Schoenberg L, et al. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation. 1996;62:599-606.
5. 5. First MR, Schroeder TJ, Monaco AP, et al. Cyclosporine bioavailability: Dosing implications and impact on clinical outcomes in select transplantation subpopulations. Clin Transplant. 1996;10:55-59.
6. 6. Neumayer HH, Farber L, Haller P, et al. Substitution of conventional cyclosporine with a new microemulsion formulation in renal transplant patients: Results after 1 year. Nephrol Dial Transplant. 1996;11:165-172.
7. 7. Vathsala A, Lee WT, Jacob E, Woo KT. Cyclosporine pharmacokinetic profiles in stable renal allograft recipients converting from Sandimmune to Neoral. Transplant Proc. 1996;28:1324-1326.
8. 8. Kahan BD, Dunn J, Fitts C, et al. The Neoral formulation: Improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients. Transplant Proc. 1994;26:2940-2943.
9. 9. Cooney GF, Jecvanandam V, Choudhury S, et al. Comparative bioavailability of Neoral and Sandimmune in cardiac transplant recipients over one year. Transplant Proc. 1998;30:1892-1894.
10. 10. Grant D, Rochon J, Levy G, et al. Comparison of the long-term tolerability, pharmacodynamics, and safety of Sandimmune and Neoral in liver transplant recipients. Ontario Liver Transplant Study Group. Transplant Proc. 1996;28:2232-2233.
11. 11. Diliz HS, Olivera MA, Kershenobich D, et al. Change of conventional cyclosporine to Neoral cyclosporine formulation in long-term liver transplant recipients. Transplant Proc. 1996;28:3348-3350.
12. 12. Melter M, Rodeck B, Kardorff R, et al. Pharmacokinetics of cyclosporine in pediatric long-term liver transplant recipients converted from Sandimmune to Neoral. Transplant Int. 1997;10:419-425.
13. 13. Rigotti P, Cadrobbi R, Baldan N, et al. Neoral versus Sandimmune in kidney-pancreas transplantation. Transplant Proc. 1997;29:2924-2926.
14. 14. Dunn SP, Cooney GF, Sommerauer J, et al. Pharmacokinetics of an oral solution of the microemulsion formulation of cyclosporine in maintenance pediatric liver transplant recipients. Transplantation. 1997;63:1762-1767.
15. 15. Hoyer PF, Boekenhamp A, Vester U, et al. Conversion from Sandimmune to Neoral and induction therapy with Neoral in pediatric renal transplant recipients. Transplant Proc. 1996;28:2259-2261.
16. 16. Kahan BD, Dunn J, Fitts C, et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat or high-fat meals. Transplantation. 1995;59:505-511.
17. 17. Benet LZ, Galeazzi RL. Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci. 1979;68:1071-1079.
18. 18. Kovarik JM, Mueller EA, Niese D. Clinical development of a cyclosporine microemulsion in transplantation. Ther Drug Monit. 1996;18:429-434.
19. 19. Keown P, Landsberg D, Halloran P, et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine emulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation. 1996;62:1744-1752.
20. 20. Wahlberg J, Wilczek HE, Fauchald P, et al. Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period. Transplantation. 1995;60:648-652.
21. 21. Cole E, Keown P, Landsberg D, et al. Safely and tolerabilily of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients: A report of the Canadian Neoral Renal Study Group. Transplantation. 1998;65:505-510.
22. 22. Pescovitz MD. Conversion from Sandimmune to Neoral in stable renal transplant recipients. Transplant Proc. 1993;28:2196-2198.